BRCA mutation carriers do not have compromised ovarian reserve

Area of Science:

• Reproductive Endocrinology
• Genetics
• Oncology

Background:

• Controversy exists regarding the impact of BRCA1/2 mutations on female fertility.
• Previous studies often used indirect fertility markers or were limited in size.
• Accurate assessment of ovarian reserve in mutation carriers is needed.

Purpose of the Study:

• To evaluate the relationship between carrying a BRCA1/2 mutation and female fertility.
• To utilize anti-Müllerian hormone (AMH) as a precise marker of ovarian reserve.
• To compare AMH levels in BRCA1/2 mutation carriers with the general population.

Main Methods:

• Studied 41 healthy BRCA1/2 mutation carriers (aged 26-40).
• Measured serum anti-Müllerian hormone (AMH) levels using ELISA.
• Compared carrier AMH levels to general population normograms and a control group.

Main Results:

• Mean AMH levels in carriers (2.71 ± 0.59 ng/mL) were comparable to the control group (2.02 ± 0.12 ng/mL, P = 0.27).
• Most carrier AMH levels fell within the 50th percentile of established normograms.
• No significant difference in ovarian reserve markers was observed between carriers and non-carriers.

Conclusions:

• Healthy BRCA1/2 mutation carriers exhibit similar ovarian reserve to age-matched non-carriers.
• AMH levels suggest comparable fertility potential in women with BRCA1/2 mutations.
• Findings may provide reassurance to female BRCA1/2 mutation carriers regarding their fertility.